Table 2: Median concentrations (pg/ml), minima and maxima of cytokines in patients with oJIA, sJIA and control subjects.

 

Recorded data (ELISA)

[median (range) pg/ml]

Patients oligoarticular arthritis [n] 10

Patients systemic arthritis  [n] 10

controls [n] 25

IL-1β                  unstimulated

34.0 (0-141.19)

76.04 (0 -719.15)

98.01 (0 -675.18)

IL-6                    unstimulated

92.0 (0-2626.06)

53.91 (0-14819.80)

349.99 (0-40579.92)

IL-10                  unstimulated

1.19 (0-4.75)

0.1 (0.1-27.42)

0.1 (0.1-179.28)

TNF-α                unstimulated

9.83 (0-32.26)

136.57 (0-2130.29)

64.96 (51.23-1065.6)

IFN-γ                 unstimulated

2.24 (0-9.24)

0.1 (0-0.1)

0.1 (0.1-22.59)

IL-1β               LPS stimulated

11001.26 (4713.39-27778.74)

1659.40 (365.85-7771.52)

1176.65 (0-2324.18)

IL-6                 LPS stimulated

12368.07 (8488.45-25293.46)

19684.29 (4620.57-29113.37)

12524.96 (2418.22-47511.88)

IL-10               LPS stimulated

789.88 (539.3-5786.66)

208.87 (0.1-802.3)

353.46 (3.58-663.24)

TNF-α             LPS stimulated

416.69 (81.71-6767.84)

1810.98 (373.02-7873.45)

1035.95 (405.05-5864.38)

IFN-γ              LPS stimulated

63.33 (7.96-368.58)

0.1 (0.1-260.99)

8.90 (0.1-259.50)

IL-1β               LPS & anakinra 

8755.14 (3657.02-16271.48)

1152.88 (378.32-3152.67)

1002.11 (134.10-1605.97)

IL-6                 LPS & anakinra

9687.29 (4724.48-36326.38)

7595.17 (1384.23-32177.63)

5102.66 (468.64-1489779.84)

IL-10               LPS & anakinra

425.23 (119.11-3404.71)

15.44 (0-250.44)

72.74 (0 -212.0)

TNF-α             LPS & anakinra

466.33 (36.16-5806.20)

566.28 (0-3824.89)

296.02 (0-1716.59)

IFN-γ              LPS & anakinra

2.45 (0-177)

0.1 (0-14)

0.1 (0-22.13)

IL-1β        LPS & adalimumab

10225.845 (4424.78-25403.25)

1973.0 (680.54-4216.76)

531.11 (136.37-2583.18)

IL-6          LPS & adalimumab

12474.815 (6037.93-22902.13)

12272.84 (3068.83-32177.63)

3944.91 (1870.02-47511.88)

IL-10        LPS & adalimumab

676.965 (363.6-4341.47)

97.766 (0-455.72)

38.62 (0-480.76)

TNF-α      LPS & adalimumab

3.035 (0-22.04)

6.14 (0-26.45)

13.22 (0-746.46)

IFN-γ       LPS & adalimumab

19.085 (7.27-261.67)

0.1 (0-29.44)

0.1 (0-11.80)